Logo image
Back
Definitive local therapy is associated with improved overall survival in metastatic cervical cancer
Journal article   Peer reviewed

Definitive local therapy is associated with improved overall survival in metastatic cervical cancer

Sriram Venigalla, David M Guttmann, Zachary D Horne, Ruben Carmona, Jacob E Shabason and Sushil Beriwal
Practical radiation oncology, v 8(6), pp e377-e385
Nov 2018
DOI: https://doi.org/10.1016/j.prro.2018.05.010
PMID: 30174248
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1016/j.prro.2018.05.010View
Published, Version of Record (VoR) Restricted

Abstract

Adenocarcinoma - mortality Adenocarcinoma - secondary Adenocarcinoma - therapy Aged Carcinoma, Squamous Cell - mortality Carcinoma, Squamous Cell - secondary Carcinoma, Squamous Cell - therapy Combined Modality Therapy Female Follow-Up Studies Humans Middle Aged Prognosis Survival Rate Uterine Cervical Neoplasms - mortality Uterine Cervical Neoplasms - pathology Uterine Cervical Neoplasms - therapy
Definitive local therapy is often used in metastatic cervical cancer to reduce morbidity associated with local tumor progression. However, the potential benefit of this therapeutic approach has not been rigorously investigated. We hypothesized that definitive local therapy is associated with improved overall survival (OS) in metastatic cervical cancer. Patients aged ≥18 years with newly diagnosed metastatic cervical cancer who were treated with chemotherapy were identified from the National Cancer Database. Patients were dichotomized into the following cohorts: definitive local therapy (defined as either concurrent chemoradiation therapy or definitive surgery) or conservative therapy (defined as systemic therapy with or without palliative radiation therapy). The association between definitive local therapy and OS was assessed using propensity score-weighted Cox proportional hazards models. Potential unmeasured confounding was assessed through sensitivity analyses. Factors associated with the receipt of definitive local therapy were identified with multivariable logistic regression. A total of 2838 patients were identified, of whom 1194 (42%) and 1644 (58%) were treated with definitive local and conservative therapy, respectively. Receipt of definitive local therapy was statistically significant, associated with less comorbidity, lower clinical T stage, and node negative disease. Compared with conservative therapy, definitive local therapy was associated with improved OS (hazard ratio: 0.57; 95% confidence interval, 0.52-0.62; P ≤ .001). The median OS rate was 19.2 months in the definitive local therapy cohort and 10.1 months in the conservative therapy cohort. These findings were robust to potential unmeasured confounding in sensitivity analyses and on landmark analyses of patients who survived at least 12 months (hazard ratio: 0.71; 95% confidence interval, 0.62-0.82; P ≤ .001). Definitive local therapy is associated with improved OS in patients with metastatic cervical cancer. These findings suggest a novel setting for the use of definitive local therapy in the metastatic setting.

Metrics

5 Record Views
30 citations in Web of Science
30 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Oncology
Radiology, Nuclear Medicine & Medical Imaging
Logo image